National Cancer Research Month: Celebrating drug discovery innovation
Drug Discovery World
MAY 30, 2023
ICIs when given alone have occasionally shown poor efficacy in some indications, and in patient subpopulations with immune-excluded or immune-cold tumours. Combining multiple ICIs has shown improved efficacy, exemplified by the approval of Nivolumab plus Ipilimumab combination in MSI-high colorectal cancer in 2018.
130 
Let's personalize your content